Conventional antiepileptic drugs suppress the excessive firing of neurons during seizures. In drug-resistant patients, treatment failure indicates an alternative important epileptogenic trigger. Two epilepsy-associated pathologies show myelin deficiencies in seizure-related brain regions: Focal Cortical Dysplasia IIB (FCD) and cortical tubers in Tuberous Sclerosis Complex (TSC). Studies uncovering white matter-pathology mechanisms are therefore urgently needed to gain more insight into epileptogenesis, the propensity to maintain seizures, and their associated comorbidities such as cognitive defects. We analyzed epilepsy surgery specimens of FCD IIB (n 5 22), TSC (n 5 8), and other malformations of cortical development MCD (n 5 12), and compared them to autopsy and biopsy cases (n 5 15). The entire lesional pathology was assessed using digital immunohistochemistry, immunofluorescence and western blotting for oligodendroglial lineage, myelin and mTOR markers, and findings were correlated to clinical parameters. White matter pathology with depleted myelin and oligodendroglia were found in 50% of FCD IIB and 62% of TSC cases. Other MCDs had either a normal content or even showed reactive oligodendrolial hyperplasia. Furthermore, myelin deficiency was associated with increased mTOR expression and the lower amount of oligodendroglia was linked with their precursor cells (PDGFRa). The relative duration of epilepsy (normalized to age) also correlated positively to mTOR activation and negatively to myelination. Decreased content of oligodendroglia and missing precursor cells indicated insufficient oligodendroglial development, probably mediated by mTOR, which may ultimately lead to severe myelin loss. In terms of disease management, an early and targeted treatment could restore normal myelin development and, therefore, alter seizure threshold and improve cognitive outcome.
INTRODUCTION
Affecting approximately 50 million people, epilepsy is one of the most common neurological diseases worldwide (WHO). Although about two-third of all epilepsy patients respond well to medical treatment with antiepileptic drugs (AEDs), 30%-40% cases are, or become, drug-resistant (18, 19) . For about one third of these patients, epilepsy surgery is an effective alternative treatment option (2) . For those who are not surgical candidates, including patients with impaired cortical development and associated myelin deficiencies, new treatment strategies are urgently needed and, therefore, studies attempting to uncover the molecular basis of epileptic seizures and epileptogenesis or detect key targets for new therapies are of crucial importance.
Malformations of cortical development (MCDs) are the most common pathologies found after epilepsy surgery in patients younger than 18 years of age (15) . The majority of these lesions are Focal Cortical Dysplasias (FCDs) (38) . FCDs are currently diagnosed according to the International League Against Epilepsy (ILAE) classification scheme introduced in 2011 (3) . This classification system distinguishes three FCD categories: Type I describes isolated focal lesions with architectural abnormalities, type II includes isolated focal lesions with architectural abnormalities and aberrant cell forms, and type III refers to cortical disorganization associated with-or adjacent to-other principal lesions (3) . Another disease increasingly treated by epilepsy surgery is Tuberous Sclerosis Complex (TSC). It is a rare genetic disorder with an estimated prevalence of between 1:6800 and 1:15000 newborns (26, 47) . Mutations in two genes, TSC1 and TSC2, are responsible for pathological constitutive activation of the highly conserved PI3K-mTOR pathway (20) . These gene mutations lead to the development of benign tumors in almost all organ systems, among them subependymal giant cell astrocytoma, cortical tubers, and neuronal migration lines (NMLs) in the brain.
Over the past decades, efforts have been made to uncover the underlying pathogenesis of FCD. Only very recently, somatic (mosaic) mutations in several genes also regulating the mTOR pathway have been identified for FCD IIA and IIB, including: PTEN; PI3KCA; AKT (17, 33) ; the DEPDC5 and NPRL3 components of the mTOR regulatory GATOR-1 complex (4, 36) ; as well as mTOR itself (8, 21, 25) . Therefore, it seems logical that these lesions have common morphological features. In addition to a thickened cortex and a blurred gray-white matter boundary, the other most prominent feature in TSC as well as in FCD IIB (detectable using pre-surgical MRI) is the white-matter deficiency. This is usually referred to as "transmantle sign" (44) .
In general, myelinogenesis is defined by the establishment of myelin sheaths and is critical for the optimization of conduction velocity, maturation, survival, and regenerative capacity of axons (27) . The cells responsible for this process are called oligodendrocytes that mature from precursor cells termed oligodendrocyte progenitor cells (OPCs) (48) . The different stages undertaken by OPCs to become mature oligodendrocytes can be assessed using several markers. For example, juvenile OPCs express high amounts of PDGFRa (42) , later additional NG2 (41); intermediate stages express mainly O4 (39); whereas fully mature oligodendrocytes express CNPase, NogoA, and MBP (35) and the older oligodendrocytes express Tppp (16, 48) . Mature cells have the capability to renew their myelin sheaths three times within 24 h (22, 28) . In its lifetime, a single oligodendrocyte is able to enwrap axons of up to 50 neurons (14, 22, 28) .
Impairment of this fragile system can have a high impact on myelination and may-in the worst case-lead to distorted or interrupted neurotransmissions (6) . The most prominent disorder linked to myelin deficiencies is multiple sclerosis (MS) (9), but abnormalities are also seen in autism and schizophrenia (13) . It is still unclear if the observed myelin pathology in epilepsy surgery specimens is primarily associated with the underlying malformative process, or is just a secondary phenomenon of ongoing epileptic seizures. Recent studies identified an association between myelin reduction and a lower number of oligodendrocytes, supporting the hypothesis that myelin pathology is the primary reason for seizures (23, 49) . However, results remain controversial: while Shepherd et al indicated a positive correlation between white matter reduction and the duration of epilepsy (35) , studies performed on patients with temporal lobe epilepsy and mild malformations of cortical development showed an increased amount of oligodendroglia compared to controls (34, 40) .
Here, we investigated the mechanisms associated with reduced myelination in patients with epilepsy because of FCD-and TSCassociated tubers. Using immunohistochemistry, we inspected the myelination of axons as well as the content of oligodendroglia cells. Immunofluorescence and western blotting were employed to study specific markers for proliferation and myelination of oligodendroglial lineage.
MATERIALS AND METHODS

Inclusion criteria and group characteristics
We reviewed pediatric patients (range 0-18 years) with MCD and drug-resistant epilepsy who underwent epilepsy surgery at the Pediatric Epilepsy Center of the Medical University Vienna. A reevaluation of corresponding formalin fixed and paraffin embedded (FFPE) resected brain material from the Neurobiobank of the Institute of Neurology was performed according to the new classification scheme (3) . Each of these individual tissue blocks had to contain sufficient white matter. Cortical tubers from patients with TSC, FCDs and mild malformations of cortical development (MMCD) were included. Five TSC cases were included from the Neurobiobank AMC Amsterdam. Age-and region-matched white matter tissue of autopsy and biopsy samples (without infiltration of tumor cells on histology) served as control group. Additional, all the cases of the control group were not allowed to show a history of epilepsy or any other neurologic disease. Besides the histological diagnosis, clinical data like gender, age, seizure frequency, relative epilepsy duration (normalized to age), AEDs, post-surgical outcome (45) and location of resected material was assessed. The study was performed according to the guidelines of good laboratory practice of the European commission, and the local ethics committee of the Medical University of Vienna gave a positive vote for the study plan (EC978/2009).
Sequencing
Somatic mutation analysis was performed with FFPE brain lesion material. For NGS, the Ion AmpliSeq TM Neurology Panel (ThermoFisher Scientific, Waltham, Massachusetts) was used for targeted multi-gene amplification of: AKT1, AKT3, ATRX, BRAF, CDK6, CIC, CTNNB1, DDX3X, DEPDC5, EZH2, FGFR1, FUBP1, H3F3A, HIST1H3b, HIST1H3c, IDH1, IDH2, KDM6A, mTOR, MYB, MYBL1, NPRL2, NPRL3, PIK3CA, PIK3R1, PIK3R2, PTCH1, PTEN, SMARCA4, SMARCB1, SMO, SUFU, TP53. The Ion AmpliSeq Library Kit 2.0 was used for libraries and Ion PGM Hi-Q Kit and Ion Chef Instrument for emulsion PCR and template preparation. The Ion PGM Hi-Q sequencing Kit was used with the Ion 318 V2 Chip and the sequencing platform was the Personal Genome Machine. About 5% was chose as background noise to determine the total number of existing non-synonymous drivergene mutations per lesion. DNA from blood samples were used for single gene analysis of TSC1 and/or TSC2 were performed with Sanger Sequencing. Unknown alterations were compared with MutationT@, PolyPhen2 and 1000Genomes Database.
Immunohistochemistry
After surgery the specimens were routinely processed for histopathology. The antibodies and dilutions ( 
ROI-based approach for slide analysis
In order to generate sufficient data for statistical analysis and to detect associations between abnormal myelination and pathology sub-types, we tested the suitability of a novel approach that focuses on the region of interest (ROI) in a particular slide. Approximately 15 slides of each brain specimen were used, each stained for a different marker. Using an especially written algorithm, the number of cells and the intensity of signals of the whole pathologic region were analyzed (Figure 1 ). The slides were scanned at 4003 magnification and each digitalized staining was visually inspected, with the NDPview software (Hamamatsu, NanoZoomer), converted to . 
Semiquantitative assessment of oligodendroglial proliferation
For determination of oligodendroglial proliferation (Ki67 and Olig2/Ki67) at least 100 nuclei were counted at high magnification (4003) and the average number of (double) positive cells was expressed as percentage (1) .
Western blotting
Western blotting was done to determine oligodendroglial lineage protein levels (NG2, Olig2, MBP) and to subsequently detect differences between epilepsy patient groups. It could only be performed in eight cases of which frozen material was available. Material from seven patients (MUV; MMCD: n 5 2; age 5 9, 13a/ FCD IIB: n 5 3; age 5 8, 17, 16a/TSC: n 5 2; age 5 3, 10a), and one autopsy control (AMC; age 5 4a) was analyzed. White matter was lysed with RIPA lysis buffer (Upstate, 20-188) plus phosphatase 2,3 (Sigma-Aldrich, P5726, P0044) and protease inhibitor cocktail (Sigma-Aldrich, P8340). After measuring protein concentration via Lowry assay, 15lg of protein was mixed with sample buffer (23 Laemmli sample buffer, BIO-RAD), loaded on SDSgels (Mini-Protean TGX Precast Gels; 4%-12%, Bio-Rad) and run for 80 min at 100 V. Tank blotting occurred with PVDF membranes at 100 V for 60 min. For the next step, membranes were 
Statistical analysis
Graphical data visualization was accomplished in GraphPad Prism (Version 7) and SPSS (Version 23.0). Statistical analysis was performed in SPSS (IBM software). Non-parametric independent Kruskal-Wallis and all-pairwise comparisons were used to analyze differences within groups. Kendall-tau b was undertaken for correlations. Categorical data was compared utilizing Chi-square. Unsupervised hierarchical clustering was performed to determine subgroups (Ward's method, squared Euclidian distances). Not significant values are indicated by n.s., P < 0.05 was considered to be significant and was indicated by stars (*).
Declaration
At the Medical University of Vienna (MUV) IHC/IF stainings, western blotting, data analysis and manuscript preparation were done. At the Academic Medical Centre (AMC, Amsterdam) sequencing, statistical counseling and project guidance were performed. Additional, AMC also provided material of five TSC patients and two controls.
RESULTS
Subjects (and material)
In total, we included material from 42 patients: eight cortical tubers from patients with TSC, 22 FCD IIB, six FCD IIA and six MMCD. The control group consisted of ten autopsy samples and five biopsy samples adjacent to a surgically removed tumor (Table  2) . Mutations within mTOR signaling were seen in all TSC (one TSC1 and seven TSC2) and some in FCD IIB samples (one SMO, one NPRL3, and one SUFU; Table 2 ).
Altered myelin content in patients with TSC and FCD IIB
To explore the differences in myelin pathology among the various forms of MCD, we applied immunohistochemistry to detect the myelin content, using MBP-, CNPase-, and MOBP staining. Lesional myelin quantification of the region of interest (ROI) was digitally assessed and compared to autopsy and biopsy white matter. In this and subsequent experiments control white matter was similarly processed. The results in Figure 2 showed that using anti-MBP antibody for detecting myelin, control brain white matter (Figure 2a As it seems that TSC and FCD IIB lesions were less myelinated compared to other MCDs and control tissue, we examined whether mTOR signaling might have an impact on myelination.
Association between mTOR activation and lowered myelin content
To explore further the observed myelin pathology and possible associations with mTOR signaling, we analyzed the levels of pS6 representing the downstream activation readout target of mTOR. In addition, we used vimentin as a marker for balloon-and giant cells. All positive cells were counted with the automated ROI-based approach and converted to cells/mm 2 . Myelin densities for MBP, CNPase, and MOBP were analyzed via the intensity of the staining and correlated to the positive cell number. Our measurements revealed a significant expression of pS6 and vimentin only in TSC and FCD IIB compared to the control ( Figure  3a , Kruskal-Wallis, pairwise comparisons, pS6 P 5 0.009*, P 5 0.000*; Figure 3f , vimentin P 5 0.015*, P 5 0.003*). To correlate these values with myelin abundance, statistical analysis was undertaken, which revealed a significant correlation between increased pS6 expression and lowered myelination (Figure 3e Hence, an increased mTOR activation might be linked to a decrease in myelination in TSC and FCD IIB and, therefore, we wanted to measure the effects of this activation on oligodendrocytes.
Different subpopulations of oligodendroglial cells based on their cell counts
To characterize the cell content and compare it to other malformations of cortical development, we used antibodies against oligodendrocyte transcription factor 2 (Olig2) and analyzed it using the ROI-based approach. For in-depth characterization of cell proliferation, antibodies against Ki67 were used in combination with a semi-quantitative rating technique. To assess whether the visible proliferating cells were indeed oligodendroglia, a co-localization of fluorescent labeled Olig2/Ki67 antibodies was performed, followed by the same semi-quantitative analysis.
Relying on the distribution of frequencies and through unsupervised clustering, we found three subpopulations based on oligodendroglial numbers (Figure 4a . One subpopulation showed a reduced amount of Olig2 positive cells (Figure 4d ) whereas the other an increased oligodendroglial number (Figure 4b ) compared to normal levels (Figure 4c ). Subsequently, all pathologies were categorized into three groups based on the oligodendroglial content of white matter: low, normal and high. In depth immunohistochemical characterization identified proliferating Ki67 positive cells within the white matter of the "high" group (median 5 3%, range 5 1%-17%) whereas this was just sporadically observed in Link between relative epilepsy duration, mTOR activation, and white matter pathology Analysis of oligodendroglial cells within the histological white matter lesions of FCD IIB and TSC revealed an inhomogeneous cell content, which could be separated into three populations (Figure 4) . To investigate group specific differences, we also subgrouped the obtained immunohistochemical data of the myelin stainings (MBP and CNPase) and compared them to mTOR activation and clinical identities. Control staining and data processing were applied using autopsy and biopsy white matter.
Further analysis of myelin pathology, shown in Figure 5 , evaluated more severe cases within the group with a low content of Olig2 positive cells. CNPase staining showed a median density of 46% (Figure 5b, sector 3b) and MBP a median of 18% (Figure 5a , sector 3b) compared to the normal group (median 99%). The population with a high Olig2 content reached the control group level within both myelin markers (Figure 5a ,b sector 1, CNPase median 5 90% "high"/91% "normal"; MBP median 5 83% "high"/94% "normal"). Analysis of clinical data (Tables 2 and 3) , such as cognitive impairment, frequency of seizures, AEDs, and postoperative outcome failed to detect significant group differences. Only the relative duration of epilepsy (normalized to age) correlated to lowered myelination of MBP and CNPase staining (Kendall-tau b; MBP R 5 20.325, P 5 0.002*, CNPase R 5 20.264, P 5 0.011; data not shown) and to mTOR activation (Kendall-tau b; pS6 R 5 0.338, P 5 0.001*, vim R 5 0.274; P 5 0.011; data not shown).
Since it was possible that an increased amount of oligodendroglia might be associated with a better myelination status, we were interested in whether the myelin pathology would be linked to an oligodendroglial renewal problem.
Burnout of oligodendroglial progenitor cells correlates to lowered oligodendroglial cell numbers
In order to clarify whether a failure within the oligodendroglial lineage might be responsible for the alteration within the myelin pathology, several markers, including PDGFRa, NogoA and Tppp, were tested immunohistochemically and analyzed with the ROIbased approach. PDGFRa was used to detect early oligodendroglial progenitor cells, NogoA for fully mature cells and Tppp for the oldest ones. To verify the results gained with immunohistochemistry, we obtained western blotting of myelin (MBP), oligodendrocytes (Olig2), and their later precursor cells (NG2), in a small cohort. In detail, three FCD IIB and two TSC white matter lysates were compared to an age-matched group of two MMCD cases and one nonepileptical autopsy case.
The immunohistochemistry results showed that mature oligodendroglial indicators like NogoA and Tppp were present in all groups (Figure 6b ; Kruskal-Wallis; no significant differences). In contrast, only the early OPC marker PDGFRa correlated to the overall number of oligodendroglia (Figure 6b , Kendall-tau b; Olig2 R 5 0.309, P 5 0.030*). Protein detected using western blotting revealed ranging conditions within oligodendroglia. Myelin content was lowered in one TSC and one FCD IIB case (Figure 6a ). Interestingly, NG2-precursor cell activation was connected to MBP 17 isoform loss.
Hence, myelin loss in combination with a lowered amount of oligodendroglia was only seen in TSC and FCD IIB, and we discuss below the possible impairment in the development of oligodendroglial progenitor cells into myelinating oligodendrocytes.
DISCUSSION
In the present study, we generated large-scale data on the myelination status in malformations of cortical development (MCD). The use of a region of interest (ROI)-based approach was shown to be efficient and reliable for data collection and analysis. Using ROIs, we were able to show for the first time that FCD IIB and TSC brains contained axons with less myelination compared to age and region matched healthy white matter. In addition, we were able to detect a novel lesion-specific mTOR activation. The lowered myelin content correlated with increased mTOR expression and the severe white matter pathology was further linked to the relative duration of epilepsy. We also identified for the first time two oligodendroglial subpopulations in patients with MCD, based on reduced numbers of oligodendroglial cells and proliferative oligodendroglial contents. Moreover, immunohistochemistry evaluation of oligodendroglial precursor cells revealed that adequate numbers of PDGFRa positive cells correlated with the amount of oligodendroglia. Western blotting showed that in those groups with specific myelin loss (MBP isoform 17), NG2 positive cells were activated, indicating delayed development into mature myelinating oligodendrocytes.
Recently, two rather arbitrary studies regarding hypomyelination and the numbers of oligodendroglial cells in epilepsy surgery specimens have been published (23, 35) . Whereas the first study showed that myelination was exclusively reduced in FCD IIB and correlated with a reduced number of oligodendroglial cells, the group of Shepherd et al, was not able to identify significant differences within oligodendroglia or OPC counts. Furthermore, in 2015 Zucca (49) were able to highlight lower amounts of oligodendroglia.
In our current study, we were also able to detect a lower amount of oligodendroglial cells in a subpopulation of FCD IIB, albeit not exclusively. We believe that the findings of our current study reflect a more continuous spectrum of white-matter pathology also in FCD IIB, which might close the gap between the two previously published contradictory results published so far. Therefore in this study, we focused on causative factors: for example, OPCs correlate with oligodendroglia, relation to mTOR activation, and the proliferative capabilities of oligodendroglia. Additionally, we expanded the analyzed cohort and included also TSC samples, which had not been analyzed in previous studies. The present results were based on quantitative immunohistochemistry, which enabled us to detect very slight differences between patient subgroups. The ROI approach employed here had the benefit of exploiting the whole pathologic region for analysis, which was kept constant during the different staining procedures compared to other reposts where one single square of an individually selected part of the lesion was used for analysis (34, 35) . To avoid additional bias from intra and interpersonal evaluation methods, standardization of the quantitative picture analysis was undertaken using a dedicated ImageJ macro specifically designed to allow full automatic processing of region-specific stainings. With this method, we evaluated the extent of myelin pathology of TSC tubers and FCD IIB compared to other MCDs. It was possible to demonstrate a significant reduction within MBP and CNPase in 62% of TSC and 50% of FCD IIB patients, while other MCDs showed no alterations. This was in line with previous studies that reported similar results (23, 35, 49) . It was also shown previously that myelin-related mRNA transcripts are reduced in the lesional cortex of FCD patients (10) .
Our study provides evidence of an association between the myelin pathology and deregulation of the mTOR pathway. A number of studies have been performed investigating the role of the AKT/ mTOR pathway in myelination [recently reviewed in Ref. (11) ]. Many of these studies used rapamycin to inhibit mTOR function and subsequently examined the function of oligodendrocytes that were less capable of producing sufficient myelin (46) . However, there is increasing evidence that mTOR signaling plays a crucial role in oligodendroglial differentiation and myelination in a timedependent manner (11) . In contrast, a large volume of evidence suggests that myelination deficits may occur in conditions with constitutive mTOR activation, such as TSC, and is also related to cognitive deficits and autism although the underlying mechanisms remain unclear (29, 37) . Very recently, it has been shown that loss of TSC2 in oligodendrocytes leads to oligodendroglial malfunction and impaired communication with neurons (7). This is in line with our finding that further supports the pathogenic link between mTOR activation and myelination deficits.
For TSC patients, an association between the TSC1/2 mutation and the mTOR pathway is well described (20) . TSC is naturally a mutation of either TSC1 or TSC2 in 85%, whereas more than half of those cases show also mosaicism (43) . Recent studies found somatic (mosaic) mutations affecting the mTOR signaling also in focal lesions of FCD II patients (4, 8, 21, 25, 32, 36) . This is a very important aspect since as far as we know, in FCD, the mutations are localized and show profound variability in cellular expression. Thus, mosaicism seems to play an important role in these lesions. However, in most FCDs, we are just analyzing the epileptogenic lesion where seizures have their origin. In terms of genetic disposition, it is definitely possible that the mosaic mutations occur also in other brain regions, but the fraction of mutated cells is not big enough to trigger malformation. Therefore, we sequenced the DNA of the lesional tissue of 22 samples of our FCD IIB cohort for the presence of validated epilepsy associated mutations, but could only detect mutations in only three patients. However, it remains possible that the other patients had mutations within different genomic regions or related genes, which might turn out to play a major role in disease development.
White-matter deficiencies are strongly associated with missing myelin-producing cells and/or glial malfunction (5, 49) . However, the number of oligodendroglial cells in MCDs is the subject of ongoing debate (12, 23, 35) . We showed for the first time that the number of oligodendroglial cells may vary from case to case even within the same type of lesion (tubers, FCD IIB). On the one hand, there was a reduced amount of cells in the case of lower myelination, as described previously (24, 49) , but on the other hand we were able to show that an increased proliferative population of oligodendroglia lead to a better myelination status. Within this context, based on our results we suggest that severe myelin deficits can indeed be associated with a decrease in Olig2-positive cells. However, normal to high amounts of oligodendroglia were previously found in normal myelination. Indeed, in patients with temporal lobe epilepsy and MMCD it has been shown before that proliferative oligodendroglial hyperplasia has no negative impact on myelination (34, 40) . In our cohort, we identified proliferative oligodendroglia for the first time also in FCD IIA, IIB, and TSC, indicating a reactive phenomenon.
Finally, we investigated oligodendroglial lineage maturation in order to clarify the mechanisms of demyelination. Compared with a multi-focal demyelinating disease such as MS, we were unable to detect signs of remyelination by immunhistochemistry. Nonetheless, also in chronic MS there is not only a decrease in the number of oligodendrocytes but also a decrease in the capacity for maturation in the remaining oligodendroglial cells (30) . Yet, failure of cortical remyelination in chronic MS may not simply result from repeated episodes of cortical demyelination affecting mature oligodendroglia, but may also require other factors that would damage OPCs at an early differentiation stage (31) . In our epilepsy cases, missing early OPCs (PDGFRa1), activation of later OPCs (NG21), and an overall lower content within mature oligodendroglia, led us to the conclusion that there is a cell breakdown (or burnout) because of insufficient maturation that prevents adequate myelination.
To conclude, here we present the first evidence that inhibition of oligodendroglial cell maturation, presumably because of overtly active mTOR signaling, may contribute to insufficient myelination associated with TSC and FCD IIB. In terms of disease management, it might be beneficial for patients to reduce the activation of mTOR signaling. Since hypo-myelination seemed to play an additional key role in disease progress, the possibility of reversing myelin disappearance could be another potential approach for treatment. This issue has not been studied so far in TSC and FCD IIB. However, previous studies in patients with MS showed that remyelination was possible, and an in vivo study conducted on rodent models of MS revealed that certain pharmaceuticals could actively support this process (9) . Assuming that hypomyelination is a reversible process, this might enable an adjuvant or even a new, targeted therapy option for patients in a selected population of TSCand FCD IIB-associated epilepsies.
